No bills from pharma, health sectors likely to come up for discussion during Winter Session
No bills from the pharma and health sectors, including the controversial National Biotechnology Regulatory Authority (NBRA) bill, may be introduced during the Winter Session.
No bills from the pharma and health sectors, including the controversial National Biotechnology Regulatory Authority (NBRA) bill, may be introduced during the Winter Session commencing on November 22 since over 100 bills already tabled in the Parliament are waiting for the look by the lawmakers.
The session which will go on till December 20 will take up the pending bills, including some crucial ones, on a priority basis instead of listing fresh bills for consideration, provided that the political turmoil does not waste the time of the Houses, sources said.
One of the prominent bills related to the pharma and health sector was the NBRA bill which was slated to be tabled on the last day of the monsoon session. However, it was stalled even the Minister concerned was about to present the bill, following stiff opposition from different parties including the ruling sections.
Though the provisional calendar was yet to be announced for the winter session, it is learnt that the Government had decided to push some of the pending bills. As many as 102 bills are pending for consideration by either House after the several sessions were disrupted continuously in the past. These pending bills include ones on land acquisition, Lokpal, whistle-blowers, money-laundering, companies, banking and forward contracts regulation.
The government had promised to address concerns of the MPs before tabling the NBRA bill, virtually pushing it back to the cold storage. The apprehensions by the Members about genetically modified crops and other products forced the government to withdraw the bill at the last minute.
Apart from the NBRA bill, a number of bills from the sector are also pending for presentation. Major Bills included HIV/AIDS bill, ethical guidelines for biomedical research on human subjects bill, Central Drug Authority (CDA) bill and ART bill.
The HIV/AIDS bill that aims to end discrimination to the HIV patients and ensuring access to treatment to them is mired in controversy and is presently stuck in the union law ministry. The tabling of ethical guidelines for biomedical research on human subjects bill in this session is also difficult as the Indian Council of Medical Research (ICMR) is reviewing the bill to make the punishment part of the bill more severe as a deterrent.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News CPHI Barcelona 2023: Loading Potential – Artificial Intelligence for Pharma Manufacturing
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: Start-ups take centre stage at CPHI Barcelona
The first episode of the CPHI Podcast Series since we attended CPHI Barcelona in October covers the Start-up market at the event, with expert Matthew Wise joining Editor Lucy Chard to discuss the event.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance